Sir Philip Hampton Swaps Royal Bank Of Scotland Group plc For GlaxoSmithKline plc… Should You?

With Royal Bank Of Scotland Group plc (LON:RBS)’s chairman moving to GlaxoSmithKline plc (LON: GSK), should you sell the former and buy the latter?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RBS

After months of speculation, it has finally been announced that Royal Bank of Scotland (LSE: RBS) (NYSE: RBS.US) chairman Sir Philip Hampton will step down from his role to take up the same job at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

This is a major loss for RBS, since Sir Philip Hampton has guided the bank through a very dark period in its history and has successfully helped it to be on course to return to profitability in the current year. With GlaxoSmithKline having endured a period of negative sentiment resulting from bribery allegations, is he the man to turn the company’s fortunes around? More importantly, should you and your money follow him from RBS to GlaxoSmithKline?

Huge Potential

Although shares in the two companies have delivered disappointing performances over the last year (RBS is down 2% and GlaxoSmithKline is down 10%), they both have considerable future potential.

In GlaxoSmithKline’s case, this centres around its drugs pipeline. Indeed, while many of its sector peers — notably AstraZeneca — have struggled to come to terms with the loss of exclusivity on key blockbuster drugs, GlaxoSmithKline continues to have a diverse and highly attractive pipeline.

Furthermore, with the sale of the company’s consumer goods businesses, Ribena and Lucozade, GlaxoSmithKline has become a pure play pharmaceutical stock that is intent on focusing all of its resources on the future development of new drugs. This bodes well for the company’s top and bottom lines, as well as for its shareholders.

Meanwhile, RBS has a bright future, too. As mentioned, its bottom line is due to return to being in the black this year, with the bank’s strategy being a major reason for this. Overseen by Sir Philip Hampton and Stephen Hester (followed by current CEO Ross McEwen), RBS has gradually reduced the size of its balance sheet through a number of disposals. This has left the bank leaner, less risky and, in the long run, better positioned to generate increasing profits.

Looking Ahead

Clearly, Sir Philip Hampton has been a key part of the RBS turnaround story. While RBS being on course to post pre-tax profits of £5.2 billion for the full year is perhaps taken for granted today, it has been a superb turnaround from the last five years when the bank lost around £17.8 billion in total. As such, he is likely to prove to be a major asset at GlaxoSmithKline, which bodes well for investors in the stock and undoubtedly makes it a more attractive investment opportunity.

As for whether RBS is now a sell, although there is still more progress to be made, the bank is well on the way to recovery. While market sentiment remains weak, with RBS trading on a price to book ratio of just 0.4, it has a bright future and appears to be well worth buying at current price levels.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of RBS, GlaxoSmithKline and AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »